Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma
ConclusionsWe confirmed significant improvement in the mOS and mPFS of unresectable and/or metastaticBRAF mutated-melanoma patients treated outside clinical trials with V + C as compared with V, with no major increase in toxicity for the combination.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research